Vyant Bio reports total revenue of $1.5M in 3Q 2021, shares strategic updates - Proactive Investors

Retrieved on: 2021-11-11 21:57:21

Tags for this article:

Click the tags to see associated articles and topics

Vyant Bio reports total revenue of $1.5M in 3Q 2021, shares strategic updates - Proactive Investors. View article details on hiswai:

Excerpt

Vyant Bio currently generates revenue from its vivoPharm and StemoniX ... data science, and engineering with global regulatory expertise.

Article found on: www.proactiveinvestors.com